Literature DB >> 3359558

Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice.

G Pratesi1, L Gianni, C Manzotti, F Zunino.   

Abstract

Primary colon tumors of different sizes and malignancy, chemically induced by methylazoxymethanol in outbred CF-1 mice, were used to investigate the antitumor effects of 5-Fluorouracil (5FU) and cis-diammine-dichloroplatinum (DDP), given weekly i.v. as single agents or in combination. When single-drug chemotherapy was tested, DDP showed higher efficacy than 5FU. In fact, in two separate experiments a significant reduction (P less than 0.05) of tumor number (TN) and tumor burden was obtained by treatment with the optimal dose of DDP (4.5 mg/kg per injection) and not by that of 5FU (52 mg/kg). When the two drugs were combined (24-h interval), studies carried out on healthy mice treated weekly i.v. showed a lower toxicity with the same doses given in the sequence 5FU-DDP than in the opposite sequence. The two drugs, delivered in the sequence 5FU followed by DDP, statistically reduced the TN and total tumor burden compared to control mice (P less than 0.05). On the other hand, the same doses in the sequence DDP followed by 5FU did not attain significant tumor reduction. The sequence dependence of the activity and toxicity of the 5FU and DDP combination observed in this experimental model should be taken into account in the design of clinical trials.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3359558     DOI: 10.1007/bf00262777

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma.

Authors:  C Dy; A Gil; S M Algarra; L A Aparicio; F Calvo; P Herranz
Journal:  Cancer Treat Rep       Date:  1986-04

2.  Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel.

Authors:  J S Kovach; C G Moertel; A J Schutt; R G Reitemeier; R G Hahn
Journal:  Cancer Chemother Rep       Date:  1973 Sep-Oct

3.  Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats.

Authors:  J M Ward
Journal:  Lab Invest       Date:  1974-04       Impact factor: 5.662

4.  Induction of adenocarcinomas of the colon in mice by weekly injections of 1,2-dimethylhydrazine.

Authors:  N Thurnherr; E E Deschner; E H Stonehill; M Lipkin
Journal:  Cancer Res       Date:  1973-05       Impact factor: 12.701

5.  Antitumor activity of cis-dichlorodiammineplatinum(II).

Authors:  M K Wolpert-DeFilippes
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

6.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

7.  Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.

Authors:  P C Amrein; S A Weitzman
Journal:  J Clin Oncol       Date:  1985-12       Impact factor: 44.544

8.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

Authors:  K J Scanlon; E M Newman; Y Lu; D G Priest
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  Alterations in hepatic and renal levels of glutathione and activities of glutathione S-transferase from rats treated with cis-dichlorodiammineplatinum-II.

Authors:  C L Litterst; S Tong; Y Hirokata; Z H Siddik
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate.

Authors:  B J Braakhuis; E J Schoevers; E C Heinerman; G Sneeuwloper; G B Snow
Journal:  Br J Cancer       Date:  1983-11       Impact factor: 7.640

View more
  8 in total

1.  Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma.

Authors:  Yuichiro Tada; Shin-Ichiro Maruya; Takashi Saotome; Kouki Miura; Tatsuo Masubuchi; Chihiro Fushimi; Isaku Okamoto; Etsuro Takeishi; Shuhei Yamada; Hiroaki Asai; Shin-Etsu Kamata
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

2.  Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.

Authors:  A Cassano; C Pozzo; D C Corsi; T Fontana; M R Noviello; A Astone; C Barone
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

3.  In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line.

Authors:  M Kuroki; S Nakano; K Mitsugi; I Ichinose; K Anzai; M Nakamura; S Nagafuchi; Y Niho
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study.

Authors:  J Jassem; F Gyergyay; S Kerpel-Fronius; T Nagykálnai; J Baumöhl; J Verweij; L Vuletic; Z Mechl; M Drozd-Lula; S Jelic
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo.

Authors:  T Shirasaka; Y Shimamoto; H Ohshimo; H Saito; M Fukushima
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.

Authors:  M C Etienne; S Bernard; J L Fischel; P Formento; J Gioanni; J Santini; F Demard; M Schneider; G Milano
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

7.  Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-kappaB independent pathway.

Authors:  K Takizawa; R Kamijo; D Ito; M Hatori; K Sumitani; M Nagumo
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

8.  Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512).

Authors:  G Pratesi; C Manzotti; G Damia; M D'Incalci
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.